Catalys Pacific, LLC
Long book
$230.7M
Q1 2026
Positions
2
Top-10 weight
100%
concentration
Last quarter
+2.1%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsCatalys Pacific, LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $230.7M US long book across 2 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: MINERALYS THERAPEUTICS INC, PHATHOM PHARMACEUTICALS INC.
Over the last 9 quarters its long book ran on average 11.7pp per quarter ahead of the S&P 500, beating the index in 3 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-9.0%
Q2 2024
+8.2%
Q3 2024
-7.6%
Q4 2024
+24.8%
Q1 2025
-11.5%
Q2 2025
+166.9%
Q3 2025
-2.5%
Q4 2025
-25.9%
Q1 2026
+2.1%
Sector allocation
Healthcare 100%
Long book by quarter
What does Catalys Pacific, own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 2 | $230.7M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 10, 2026 | 2 | $310.5M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 2 | $351.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 13, 2025 | 2 | $131.7M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR/ARESTATEMENT | Aug 13, 2025 | 2 | $148.7M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 2 | $148.7M | SEC ↗ | |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 2 | $115.9M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 12, 2024 | 3 | $125.4M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 3 | $132.5M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 3 | $148.1M | canonical | SEC ↗ |